Creative Biolabs Connects Phage Display, pH-Dependent Binder Screening, and Antibody Sequencing
Complementary research capabilities address antibody candidate discovery, environment-responsive binder screening, and mass spectrometry-based sequence characterisation.
Creative Biolabs highlights a portfolio of antibody research capabilities spanning monoclonal antibody discovery, pH-sensitive binder identification, and antibody sequence characterisation. The approaches combine phage display, customised pH-dependent screening, and mass spectrometry-based peptide analysis to address different questions in antibody research.
These services address complementary but distinct research needs. Phage display can support the identification of new antibody candidates, while pH-dependent screening can be incorporated when a project requires environment-responsive binding properties. For researchers working with existing antibodies or candidates requiring sequence confirmation, mass spectrometry-based sequencing provides an additional characterisation route. The combination of services depends on the starting material and the project’s scientific objectives.
Monoclonal Antibody Discovery Through Phage Display
Antibody discovery requires strategies suited to the biological characteristics of the target, the desired antibody format, and project constraints. Immunised libraries may be useful when a suitable target-specific immune response can be generated, while naïve and synthetic or semi-synthetic libraries offer alternative routes when immunisation is impractical or undesirable. Library selection should therefore be guided by target properties and discovery objectives rather than assuming that one library type is universally preferable.
Through its Monoclonal Antibody Discovery Services, Creative Biolabs provides phage display-based approaches involving library construction or selection, biopanning, enrichment, and candidate validation. Available antibody formats include scFv, Fab, and single-domain antibodies (sdAbs). Selected candidates may undergo affinity and specificity assessment, epitope binning, competition studies, and cell-based functional evaluation. Further options can include affinity maturation, humanisation, stability and solubility optimisation, and antibody format or Fc engineering.
Identifying Binders with pH-Dependent Binding Properties
The desired direction of pH-dependent binding is application-specific. Some projects seek strong binding near physiological pH with reduced binding under acidic conditions, for example when investigating release or recycling mechanisms. Other studies may explore preferential binding within a defined acidic environment, including aspects of the tumour microenvironment. These are distinct design objectives and should not be treated as interchangeable.
The pH-Sensitive Binder Discovery Services cover both pH-sensitive peptide discovery and monoclonal antibody discovery. Phage display libraries and customised screening conditions can be used to identify binders with different binding behaviours across selected pH ranges. Conditions such as pH 5.5, 6.0, and 7.4 are examples; the actual screening range and direction of response should be tailored to the project’s biological question.
Available formats include scFv, Fab, sdAb, and peptide binders. Evaluation can involve clonal validation, binding kinetics assessment, comparative binding curves, pH-response profiling, and sequencing. Importantly, pH responsiveness should not be judged solely from endpoint binding signals; kinetics, reversibility, and stability under the relevant conditions may also need to be assessed.
Mass Spectrometry-Based Antibody Sequencing
Accurate antibody sequence determination supports molecular characterisation, sequence verification, and subsequent engineering. The Next-Generation Antibody Sequencing service uses Database Assisted Shotgun Sequencing (DASS), combining liquid chromatography-tandem mass spectrometry (LC-MS/MS), de novo peptide sequencing, and computational sequence assembly.
Unlike nucleic acid-based next-generation sequencing, this approach uses mass spectrometry-derived peptide information to reconstruct antibody protein sequences. It can be particularly relevant when researchers have a purified antibody protein but lack complete nucleotide sequence information, or when sequence characterisation is needed for an existing antibody reagent.
The service covers variable-region, variable-plus-leader-region, and full-length heavy- and light-chain sequencing. Particular attention may be given to CDR3 characterisation and to leucine/isoleucine differentiation, since these amino acids are isobaric and can be difficult to distinguish using conventional mass measurements alone. Analysis of non-standard formats, including fluorochrome-conjugated antibodies and IgMs, is subject to sample characteristics and method suitability.
Discuss Your Antibody Research Requirements
Researchers developing new antibody candidates, investigating pH-dependent binding properties, or seeking sequence characterisation of existing antibodies can explore the specialised research services described above. Project teams are encouraged to share target information, antibody format, sample characteristics, and research objectives to discuss suitable discovery, screening, or sequencing approaches.
These approaches are complementary rather than universally sequential. Selecting the appropriate capability—or combination of capabilities—depends on the research question and the material already available.
All listed services are intended for research use only and are not intended for diagnostic or therapeutic procedures.
About Creative Biolabs
Creative Biolabs is a biotechnology service provider specialising in antibody discovery, engineering, characterisation, and custom development solutions. The company supports research organisations and biotechnology developers through technology platforms and customised services for diverse molecular research challenges.
